Assessment of STELARA (Ustekinumab) and Tumor Necrosis Factor Alpha Inhibitor Therapies in Patients With Psoriatic Arthritis in Standard Health-Care Practice; A Prospective, Observational Cohort
Phase of Trial: Phase IV
Latest Information Update: 06 Oct 2017
At a glance
- Drugs Ustekinumab (Primary)
- Indications Psoriatic arthritis
- Focus Therapeutic Use
- Acronyms PsaBio
- Sponsors Janssen Pharmaceutica
- 17 Mar 2017 Planned End Date changed from 1 Dec 2020 to 22 Dec 2020.
- 02 Feb 2016 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
- 15 Dec 2015 New trial record